ArticleCNS neuroscience & therapeutics2025
Triptolide Inhibits Epileptic Seizures by Rescuing the Neuroinflammation-Related GABAergic Dysfunction in Mice.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Atmospheric Aerosol Neurotoxicity and Parkinson's Disease: Mechanisms and Perspectives.Journal of biochemical and molecular toxicology · 2026Review
- Research progress of traditional Chinese medicine interventions for aging-related nervous system diseases.Biogerontology · 2026Review
- Triptolide Inhibits Epileptic Seizures by Rescuing the Neuroinflammation-Related GABAergic Dysfunction in Mice.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aims to evaluate the antiepileptic effect of triptolide (TPL), a strong anti-inflammatory and immunosuppressive diterpenoid compound from a Chinese herb medicine Tripterygium wilfordii Hook F (TWHF).
methodsThe pentylenetetrazol (PTZ)-induced seizure model, maximal electroshock seizure (MES) model, corneal (6 Hz) kindling model, and kainic acid (KA) mouse model were used to assess the antiepileptic effect of TPL. EEG recording and behavioral tests were used to evaluate the disease-modifying effects of TPL in epileptic conditions. Extracellular recording combined with optogenetics was used to evaluate the effect of TPL on hippocampal GABAergic inhibition in vivo.
resultsThough intragastric administration of TPL (50 μg/kg) had no direct anticonvulsive effect in normal mice, it retarded corneal kindling acquisition in mice and reduced the seizure severity in corneal kindled mice. Meanwhile, intragastric administration (10 or 50 μg/kg) of TPL exhibited disease-modifying effects in the established KA mouse model of temporal lobe epilepsy (TLE). Extracellular recording combined with optogenetics showed that TPL improved the hippocampal GABAergic "braking effect" in epileptic mice. Furthermore, bioinformatics analysis predicts IL-1β as a key target for the antiepileptic effect of TPL. TPL reduced the level of IL-1β in the hippocampus of KA-induced epileptic mice, while focal injection of IL-1β (5 ng in 1 μL saline) attenuated the hippocampal GABAergic "braking effect" in normal mice. Focal injection of TPCA-1 (an IKK-2/NF-κB inhibitor, 600 ng in 1 μL 1% DMSO) partly recovered the IL-1β-induced attenuation of the GABAergic "braking effect".
conclusionThis study indicates that a low dose of TPL may inhibit epilepsy by potentially rescuing dysfunction in hippocampal GABAergic neural circuits related to neuroinflammation in mice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.